✦ LIBER ✦

Expression of the SART1 tumor rejection antigen in renal cell carcinoma

✍ Scribed by Shintaku, I. ;Kawagoe, N. ;Yutani, S. ;Hoshi, S. ;Orikasa, S. ;Yoshizumi, O. ;Itoh, K.

Publisher: Springer
Year: 2000
Tongue: English
Weight: 157 KB
Volume: 28
Category: Article
ISSN: 0300-5623
DOI: 10.1007/s002400000103

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Expression of the tumor-rejection antige

Expression of the tumor-rejection antigen SART1 in brain tumors

✍ Toshihiro Imaizumi; Terukazu Kuramoto; Kazuko Matsunaga; Shigeki Shichijo; Shige 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 French ⚖ 156 KB 👁 2 views

We have reported a tumor-rejection antigen, SART1 259 , possessing tumor epitopes capable of inducing cytotoxic T lymphocytes (CTLs) in epithelial-cancer patients. This study investigated the expression of SART1 259 antigen in brain tumors, to explore for a potential molecule for use in specific imm

Expression of the SART-1 tumor rejection

Expression of the SART-1 tumor rejection antigen in breast cancer

✍ Mayumi Kawamoto; Shigeki Shichijo; Yasuhisa Imai; Toshihiko Imaizumi; Toshihiro 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 French ⚖ 127 KB 👁 2 views

We investigated in breast cancers the expression of the SART-1 gene encoding tumor rejection antigens. SART-1 mRNA was expressed in all of the samples tested. The SART-1 800 antigen was detectable in 20 of 50 (40%) breast cancer tissues and all breast cancer cell lines tested, but not in normal brea

Expression of the SART1 tumor-rejection

Expression of the SART1 tumor-rejection antigens in colorectal cancers

✍ Teruo Sasatomi; Hideaki Yamana; Shigeki Shichijo; Shoko Tanaka; Torahiko Okamura 📂 Article 📅 2000 🏛 Springer 🌐 English ⚖ 644 KB

Expression of tumor rejection antigens i

Expression of tumor rejection antigens in colorectal carcinomas

✍ Teruo Sasatomi; Yuichi Suefuji; Kazuko Matsunaga; Hideaki Yamana; Yoshiaki Miyag 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 143 KB

## Abstract ## BACKGROUND The authors recently reported that the SART2 and SART3 antigens encode tumor epitopes recognized by HLA‐A24‐restricted and tumor‐specific cytotoxic T lymphocytes (CTLs) established from esophageal carcinoma patients. The current study investigated these antigens to explor

T-cell receptor Vβ gene usage by T cells

T-cell receptor Vβ gene usage by T cells reactive with the tumor-rejection antigen SART-1 in oral squamous cell carcinoma

✍ Wataru Kumamaru; Seiji Nakamura; Tsutomu Kadena; Akira Yamada; Eiji Kawamura; Ma 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 French ⚖ 425 KB

## Abstract We recently described that the SART‐1~690–698~ peptide could induce HLA‐A24‐restricted cytotoxic T lymphocytes (CTLs), which recognize the SART‐1 tumor cells from peripheral blood mononuclear cells (PBMCs) of HLA‐A24^+^ cancer patients. In our study, in 5 of 14 HLA‐A24^+^ patients with

Human esophageal carcinomas frequently e

Human esophageal carcinomas frequently express the tumor-rejection antigens of MAGE genes

✍ Hiroshi Inoue; Masaki Mori; Jian Li; Koshi Mimori; Masayuki Honda; Hideaki Nakas 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 French ⚖ 462 KB

The human genes MAGE-I and -3 encode melanoma peptide antigens that are recognized by autologous cytotoxic T lymphocytes. Tumors expressing MAGE genes are potential targets for cancer immunotherapy, because MAGE genes are expressed only in tumor tissue and not in any normal tissue except testis and